ReviewFEMS microbiology reviews2022
Global colistin use: a review of the emergence of resistant Enterobacterales and the impact on their genetic basis.
Review in FEMS microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Prevalence of colistin resistance in clinicalFuture microbiology · 2025Pooled it
- The prevalence of colistin resistance in clinical Stenotrophomonas maltophilia isolates worldwide: a systematic review and meta-analysis.BMC microbiology · 2023Pooled it
- Identification ofAntibiotics (Basel, Switzerland) · 2026Article
- Negative-Ion Mode MALDI-TOF MS Combined with Machine Learning for the Rapid Identification of Colistin-ResistantACS omega · 2026Article
- Domestic travel as a driver for the dissemination ofAntimicrobial agents and chemotherapy · 2026Article
- Persistence and Environmental Dissemination of a NovelMicroorganisms · 2026Article
- Perspectives on Colistin-An Old Antibiotic with Renewed Relevance in Modern Medicine.International journal of molecular sciences · 2026Review
- Emergence of Polymyxin Resistance Driven by a PhoQ Mutation in KPC-2-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- Nationwide genomic surveillance of carbapenem- and colistin-resistant Klebsiella pneumoniae bloodstream isolates in Thailand (2020-2024).Scientific reports · 2026Article
- Colistin Resistance in Gram-Negative Bacteria: Mechanisms, Transmission, and Novel Intervention Strategies.Microorganisms · 2026Review
- Characterisation ofFrontiers in veterinary science · 2026Article
- The efficacy and safety of colistimethate sodium in the treatment of carbapenem-resistant Gram-negative bacilli: a real-world observational study.Frontiers in cellular and infection microbiology · 2026Observational
- Proteome-wide remodelling in Klebsiella pneumoniae during step-wise adaptive evolution against colistin.PloS one · 2026Article
- Persistence of colistin-resistant Escherichia coli and the mcr-1 gene in the poultry chain, after the colistin ban.Veterinary research communications · 2025Article
- Tracking Global Transmission Dynamics of the Plasmid-MediatedMicroorganisms · 2025Article
- Genomic evolution and stability of the mcr-1-harboring IncI2 plasmid in the presence and absence of colistin.BMC genomics · 2025Article
- Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.Folia microbiologica · 2025Review
- Dissemination dynamics of colistin resistance genes mcr-9 and mcr-10 across diverse Inc plasmid backbones.Communications medicine · 2025Article
- The Gut Microbiome and Colistin Resistance: A Hidden Driver of Antimicrobial Failure.International journal of molecular sciences · 2025Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dramatic global rise of MDR and XDR Enterobacterales in human medicine forced clinicians to the reintroduction of colistin as last-resort drug. Meanwhile, colistin is used in the veterinary medicine since its discovery, leading to a steadily increasing prevalence of resistant isolates in the livestock and meat-based food sector. Consequently, transmission of resistant isolates from animals to humans, acquisition via food and exposure to colistin in the clinic are reasons for the increased prevalence of colistin-resistant Enterobacterales in humans in the last decades. Initially, resistance mechanisms were caused by mutations in chromosomal genes. However, since the discovery in 2015, the focus has shifted exclusively to mobile colistin resistances (mcr). This review will advance the understanding of chromosomal-mediated resistance mechanisms in Enterobacterales. We provide an overview about genes involved in colistin resistance and the current global situation of colistin-resistant Enterobacterales. A comparison of the global colistin use in veterinary and human medicine highlights the effort to reduce colistin sales in veterinary medicine under the One Health approach. In contrast, it uncovers the alarming rise in colistin consumption in human medicine due to the emergence of MDR Enterobacterales, which might be an important driver for the increasing emergence of chromosome-mediated colistin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.